Evidence map›Paper›PMID 28029154›Full record

ReviewNature reviews. Nephrology2017

Changes in the worldwide epidemiology of peritoneal dialysis.

Philip Kam-Tao Li, Kai Ming Chow, Moniek W M Van de Luijtgaarden, David W Johnson, Kitty J Jager, Rajnish Mehrotra, Sarala Naicker, Roberto Pecoits-Filho, Xue Qing Yu, Norbert Lameire

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 288 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
288citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04238338 unknown statusnot on this mapstarted 2020, after this paper: background citation

Association of Monocyte / Lymphocyte Ratio With Risk of Death and Cardiovascular Events in Peritoneal Dialysis Patients

TypeobservationalSponsorZhujiang HospitalRan2020 to 2022Enrolled266ConditionsPeritoneal Dialysis, InflammationArmsmonocyte / lymphocyte ratio
NCT05449067 nacompletednot on this mapstarted 2022, after this paper: background citation

Nocturnal Automated Versus Continuous Ambulatory Peritoneal Dialysis in Patients With End-Stage Kidney Disease: A Multicenter, Randomized, Open-Label, Crossover Non-Inferiority Trial

TypeinterventionalSponsorNanfang Hospital, Southern Medical UniversityRan2022 to 2026Enrolled137ConditionsEnd-Stage Kidney Disease, Peritoneal DialysisArmsNocturnal automated peritoneal dialysis (APD), Continuous Ambulatory Peritoneal Dialysis (CAPD)
3 · Its place in the literature

Who cites it

288 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Peritoneal dialysis versus haemodialysis for people commencing dialysis.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Renal failure · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Dynamic changes in serum albumin and ferritin indicate higher risk of early-onset peritonitis in peritoneal dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  18. Article
  19. Article
  20. Article

228 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Philip Kam-Tao LiDepartment of Medicine and Therapeutics, Carol &Richard Yu PD Research Centre, Chinese University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong.
Kai Ming ChowDepartment of Medicine and Therapeutics, Carol &Richard Yu PD Research Centre, Chinese University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong.
Moniek W M Van de LuijtgaardenERA-EDTA Registry, Department of Medical Informatics, Academic Medical Centre, University of Amsterdam, PO Box 22700, Amsterdam 1100 DE, Netherlands.
David W JohnsonDepartment of Nephrology, Division of Medicine, ARTS Building, University of Queensland at Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia.
Kitty J JagerERA-EDTA Registry, Department of Medical Informatics, Academic Medical Centre, University of Amsterdam, PO Box 22700, Amsterdam 1100 DE, Netherlands.
Rajnish MehrotraKidney Research Institute and Harborview Medical Center, Division of Nephrology, University of Washington, 325 9th Avenue, BOX 359606, Seattle, Washington 98104, USA.
Sarala NaickerDepartment of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg, 2193, South Africa.
Roberto Pecoits-FilhoSchool of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Brazil.
Xue Qing YuDepartment of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Norbert LameireUniversity Hospital Gent, 185, De Pintelaan, BE-9000 Gent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the global burden of chronic kidney disease continues to increase, so does the need for a cost-effective renal replacement therapy. In many countries, patient outcomes with peritoneal dialysis are comparable to or better than those with haemodialysis, and peritoneal dialysis is also more cost-effective. These benefits have not, however, always led to increased utilization of peritoneal dialysis. Use of this therapy is increasing in some countries, including China, the USA and Thailand, but has proportionally decreased in parts of Europe and in Japan. The variable trends in peritoneal dialysis use reflect the multiple challenges in prescribing this therapy to patients. Key strategies for facilitating peritoneal dialysis utilization include implementation of policies and incentives that favour this modality, enabling the appropriate production and supply of peritoneal dialysis fluid at a low cost, and appropriate training for nephrologists to enable increased utilization of the therapy and to ensure that rates of technique failure continue to decline. Further growth in peritoneal dialysis use is required to enable this modality to become an integral part of renal replacement therapy programmes worldwide.

Indexed as

Global HealthHumansKidney Failure, ChronicPeritoneal Dialysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.